$54.90
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

the drug has anti-inflammatory, decongestant and analgesic effects. escin reduces the activity of lysosomal hydrolases, which prevents the splitting of mucopolysaccharides in the walls of the capillaries and in the connective tissue that surrounds them, and thus normalizes the increased vascular tissue permeability and has anti-exudative (decongestant), anti-inflammatory and analgesic effects. the drug increases vascular tone, indicates moderate immunocorrective and hypoglycemic effects.

Pharmacokinetics Not studied.

Indications

As part of the complex therapy of cerebral edema of traumatic, non-traumatic and postoperative genesis, including with intracranial hemorrhage, increased intracranial pressure and swelling-swelling phenomena.

Swelling of the spinal cord of traumatic, non-traumatic, postoperative origin.

Liquor-venous disorders in chronic cerebrovascular accidents (CMVD) and vegetative-vascular dystonia.

Edema of soft tissues with the involvement of the musculoskeletal system, accompanied by local disorders of their blood supply and pain; edematous-pain syndromes of the spine, limbs; severe violations of the venous circulation of the lower extremities in acute thrombophlebitis, accompanied by edematous-inflammatory syndrome.

Application

The drug is administered only in / in or in / drip. intra-arterial administration of the drug is unacceptable.

The drug is recommended to be administered by slow intravenous infusion after dilution to a volume of 15-50 ml of 0.9% sodium chloride solution.

The optimal recommended duration of treatment is 5-10 days of daily administration of the drug.

The maximum daily dose for adults is 25 ml.

Recommended daily doses:

For adults: the recommended daily dose of the drug is 5-10 ml.

In conditions that threaten the patient’s life, the daily dose is increased to 20 ml, divided into two injections, the course of treatment is up to 8 days.

In case of cerebro-venous disorders in chronic heart disease and vegetative-vascular dystonia - 10 ml / day, the treatment course is 10 days.

In children, a single dose is:

1 year – 5 years - 0.22 mg of L-lysine escinate per 1 kg of body weight;

5-10 years - 0.18 mg / kg body weight; ≥10 years - 0.15 mg / kg. The drug is administered twice a day. The duration of treatment is from 2 to 8 days, depending on the condition of the patient and the effectiveness of therapy.

Contraindications

Hypersensitivity to l-lysine to escinate and / or other components of the drug; active continuation of bleeding, which is accompanied by unstable hemodynamics; severe renal impairment; severe liver dysfunction.

Side effects

With individual hypersensitivity to escin in individual patients, the following are possible:

allergic reactions: skin rash (papular, petechial, erythematic), itching, flushing of the skin, hyperthermia, urticaria, in rare cases - Quinckes edema, anaphylactic shock;

on the part of the central and peripheral nervous system: headache, dizziness, tremor, paresthesia, in isolated cases - shaky gait, imbalance, short-term loss of consciousness;

from the liver and biliary system: increased levels of transaminases and bilirubin;

from the gastrointestinal tract: nausea, in isolated cases - vomiting, diarrhea, abdominal pain;

from the cardiovascular system: arterial hypotension, hypertension, tachycardia, pain behind the sternum;

on the part of the respiratory system: in isolated cases - a feeling of lack of air, shortness of breath, bronchial obstruction, dry cough;

local reactions: burning sensation along the vein during administration, phlebitis, pain and swelling at the injection site;

others: general weakness, chills, sensation of heat, back pain, hyperhidrosis.

special instructions

In some patients with hepatocholecystitis, when using the drug, a short-term increase in the activity of transaminases and bilirubin (direct fraction) in the blood plasma is possible, which is not dangerous for the patient and does not require drug withdrawal.

During pregnancy and breastfeeding. The use of the drug during pregnancy and lactation is contraindicated. Breastfeeding should be discontinued during treatment.

Children. The drug is contraindicated in children under the age of 1 year.

The ability to influence the reaction rate when driving vehicles and working with other mechanisms. At the moment, there are no reports, however, when using the drug, the possibility of developing suspected adverse reactions from the nervous system should be taken into account.

Interactions

In the treatment of l-lysine with escinate, it is possible to prescribe other drugs (anti-inflammatory, analgesics, antimicrobial) with appropriate indications.

The drug should not be used simultaneously with aminoglycosides because of the possibility of increasing their nephrotoxicity. In the case of prolonged anticoagulant therapy, which was carried out before the appointment of L-lysine of escinate, or if necessary, the simultaneous use of L-lysine of escinate and anticoagulants, it is necessary to adjust the dose of the latter (reduce the dose) and monitor the prothrombin index.

The binding of escin to blood plasma proteins decreases with the simultaneous use of cephalosporin antibiotics, which can increase the concentration of free escin in the blood with a risk of side effects of the latter.

Overdose

Symptoms: fever, tachycardia, menorrhagia, nausea, heartburn, epigastric pain.

Treatment: symptomatic therapy.

Storage conditions

At a temperature not exceeding 25 ° C.

Tags: lysine escinate